Fol. Biol. 2016, 62, 40-46
https://doi.org/10.14712/fb2016062010040
Effect of DSS on Bacterial Growth in Gastrointestinal Tract
References
1. , H., Rohde, M., Guzmán, C. A. (2000) Vectors to achieve selective expression of vaccine antigens within eukaryotic cells using Salmonella spp. as carrier strains. FEMS Microbiol. Lett. 182, 219-223.
<https://doi.org/10.1111/j.1574-6968.2000.tb08898.x>
2. , D. C., Carding, S.R. (2007) Inflammatory bowel disease: cause and immunobiology. Lancet 369, 1627-1640.
<https://doi.org/10.1016/S0140-6736(07)60750-8>
3. , I., Beggiao, E., Brun, P., Barzon L., Goussard, S., Manganelli, R., Grillot-Courvalin, C., Palù, G. (2005) Engineered E. coli delivers therapeutic genes to the colonic mucosa. Gene Ther. 12, 1070-1078.
<https://doi.org/10.1038/sj.gt.3302493>
4. , B., Lodínová-Žádníková, R., Enders, C., Sonnenborn, U., Schulze, J., Tlaskalová-Hogenová, H. (2002) Specific proliferative and antibody responses of premature infants to intestinal colonization with nonpathogenic probiotic E. coli strain Nissle 1917. Scand J. Immunol. 55, 204-209.
<https://doi.org/10.1046/j.1365-3083.2002.01005.x>
5. , A., Guzmán, C. A., Gerstel, B., Wachholz, P., Timmis, K. N., Wehland, J., Chakraborty, T., Weiss, S. (1997) Oral somatic transgene vaccination using attenuated S. typhimurium. Cell 91, 765-775.
<https://doi.org/10.1016/S0092-8674(00)80465-1>
6. , R., Behuliak, M., Palffy, R., Celec, P., Li, C. J. (2011) Gene therapy for cancer: bacteria-mediated anti-angiogenesis therapy. Gene Ther. 18, 425-431.
<https://doi.org/10.1038/gt.2010.176>
7. , R., Palffy, R., Celec, P. (2012) Recombinant probiotic therapy in experimental colitis in mice. Folia Biol. (Praha) 58, 238-245.
<https://doi.org/10.14712/fb2012058060238>
8. , R., Bartonova, A., Celec, P. (2013) Therapeutic DNA vaccination and RNA interference in inflammatory bowel disease. Int. J. Mol. Med. 32, 1-5.
<https://doi.org/10.3892/ijmm.2013.1388>
9. , R., Wagnerova, A., Celec, P. (2014) Effects of bacteria mediated reprogramming and antibiotic pretreatment on the course of colitis in mice. Mol. Med. Rep. 10, 983-988.
<https://doi.org/10.3892/mmr.2014.2244>
10. , A. J., Huffnagle, G. B. (2014) The microbiome and regulation of mucosal immunity. Immunology 142, 24-31.
<https://doi.org/10.1111/imm.12231>
11. , R., Kamhi Trop, T. (2014) Intestinal mocrobiota, probiotics and prebiotics in inflammatory bowel disease. Gastroenterol. Hepatol. 20, 11505-11524.
12. , R., Behuliak, M., Gardlík, R., Jáni, P., Kádaši, Ľ., Turňa, J., Celec, P. (2010) Oral in vivo bactofection in dextran sulfate sodium treated female Wistar rats. Folia Biol. (Krakow) 58, 171-176.
<https://doi.org/10.3409/fb58_3-4.171-176>
13. , R., Gardlik, R., Behuliak, M., Jani, P., Balakova, D., Kadasi, L., Turna, J., Celec, P. (2011) Salmonella-mediated gene therapy in experimental colitis in mice. Exp. Biol. Med. 236, 177-183.
<https://doi.org/10.1258/ebm.2010.010277>
14. , A. M., Mirsepasi, H., Halkjær, S. I., Mortensen, E. M., Nordgaard-Lassen, I., Krogfelt, K. A. (2014) Ciprofloxacin and probiotic Escherichia coli Nissle add-on treatment in active ulcerative colitis: a double-blind randomized placebo controlled clinical trial. J. Crohns Colitis 8, 1498-1505.
<https://doi.org/10.1016/j.crohns.2014.06.001>
15. , S., Xu, B., Kong, X., Wei, N., Liu, J., Wu, K. (2014) Preventive effects of Escherichia coli strain Nissle 1917 with different courses and different doses on intestinal inflammation in murine model of colitis. Inflamm. Res. 63, 873-883.
<https://doi.org/10.1007/s00011-014-0761-1>
16. , A. M., Gunzer, F., Deppenmeier, S., Tapadar, D., Hunger, J. K., Schmidt, M. A., Buer, J., Bruder, D. (2005) Intestinal immunity of Escherichia coli NISSLE 1917: a safe carrier for therapeutic molecules. FEMS Immunol. Med. Microbiol. 43, 373-384.
<https://doi.org/10.1016/j.femsim.2004.10.023>
17. , R. A., Rausch, S., Ebner, F., Günzel, D., Richter, J. F., Hering, N. A., Schulzke, J.-D., Kühl, A. A., Keles, A., Janczyk, P., Nöckler, K., Wieler, L. H., Hartmann, S. (2014) A transgenic probiotic secreting a parasite immunomodulator for site-directed treatment of gut inflammation. Mol. Ther. 22, 1730-1740.
<https://doi.org/10.1038/mt.2014.125>
18. , T., Parker, N., Ylä-Herttuala, S. (2013) History of gene therapy. Gene 525, 162-169.
<https://doi.org/10.1016/j.gene.2013.03.137>
19. , S., Neufert, C., Weigmann, B., Neurath, M. F. (2007) Chemically induced mouse models of intestinal inflammation. Nat. Protoc. 2, 541-546.
<https://doi.org/10.1038/nprot.2007.41>
20. , R. J., Podolsky, D. K. (2007) Unravelling the pathogenesis of inflammatory bowel disease. Nature 448, 427-434.
<https://doi.org/10.1038/nature06005>
